Identification of urinary soluble E-cadherin as a novel biomarker for diabetic nephropathy

Diabetes/Metabolism Research and Reviews

Volumn 25, Issue 3, 2009, Pages 232-241

  Jiang, Hongjuan ^a   Guan, Guangju ^a   Zhang, Rui ^b   Liu, Gang ^a   Cheng, Jing ^a   Hou, Xianghua ^a   Cui, Yazhou ^c  

^a THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY OF FINANCE AND ECONOMICS   (China)

^c BEIJING HOSPITAL   (China)

Author keywords

Diabetic nephropathy; DIGE; E cadherin; Urinary proteomics

Indexed keywords

CREATININE; HUMAN INSULIN; UVOMORULIN; BIOLOGICAL MARKER; CADHERIN;

ADULT; ALBUMINURIA; AMINO ACID SEQUENCE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL ELECTROPHORESIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; KIDNEY TUBULE EPITHELIUM; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEOMICS; SENSITIVITY AND SPECIFICITY; UPREGULATION; URINALYSIS; URINE LEVEL; WESTERN BLOTTING; AGED; KIDNEY; METABOLISM; MIDDLE AGED; SOLUBILITY; TWO DIMENSIONAL GEL ELECTROPHORESIS; URINE;

ADULT; AGED; ALBUMINURIA; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CADHERINS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; MALE; MIDDLE AGED; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SOLUBILITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 65649108618     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.940     Document Type: Article

References (34)

1. US Renal Data System. USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2003.
2. Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 2000; 160: 1093-1100.
3. Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient?. Diabetes 2000; 49: 1399-1408.
4. Tabaei BP, Al-Kassab AS, Ilag LL, Zawacki CM, Herman WH. Does microalbuminuria predict diabetic nephropathy? Diabetes Care 2001; 24: 1560-1566.
5. Dihazi H, Müller GA. Urinary proteomics: a tool to discover biomarkers of kidney diseases. Expert Rev Proteomics 2007; 4: 39-50.
6. Goligorsky MS, Addabbo F, O'Riordan E. Diagnostic potential of urine proteome: a broken mirror of renal diseases. J Am Soc Nephrol 2007; 18: 2233-2239.
7. Thongboonkerd V, Klein JB, Jevans AW, McLeish KR. Urinary proteomics and biomarker discovery for glomerular diseases. Contrib Nephrol 2004; 141: 292-307.
8. Rao PV, Lu X, Standley M, et al. Proteomic identification of urinary biomarkers of diabetic nephropathy. Diabetes Care 2007; 30: 629-637.
9. Meier M, Kaiser T, Herrmann A, et al. Identification of urinary protein pattern in Type 1 diabetic adolescents with early diabetic nephropathy by a novel combined proteome analysis. J Diabetes Complicat 2005; 19: 223-232.
10. Mischak H, Kaiser T, Walden M, et al. Proteomic analysis for the assessment of diabetic renal damage in humans. Clin Sci (Lond) 2004; 107: 485-495.
11. Jain S, Rajput A, Kumar Y, Uppuluri N, Arvind AS, Tatu U. Proteomic analysis of urinary protein markers for accurate prediction of diabetic kidney disorder. J Assoc Physicians India 2005; 53: 513-520.
12. Dihazi H, Müller GA, Lindner S, et al. Characterization of diabetic nephropathy by urinary proteomic analysis: identification of a processed ubiquitin form as a differentially excreted protein in diabetic nephropathy patients. Clin Chem 2007; 53: 1636-1645.
13. Sharma K, Lee S, Han S, et al. Two-dimensional fluorescence difference gel electrophoresis analysis of the urine proteome in human diabetic nephropathy. Proteomics 2005; 5: 2648-2655.
14. Chan AO, Chu KM, Lam SK, et al. Early prediction of tumor recurrence after curative resection of gastric carcinoma by measuring soluble E-cadherin. Cancer 2005; 104: 740-746.
15. Chakraborty J, Below AA, Solaiman D. Tamm-Horsfall protein in patients with kidney damage and diabetes. Urol Res 2004; 32: 79-83.
16. Rowe DJF, Anthony F, Polak A, Shaw K, Ward CD. Retinol-binding protein as a small molecular weight marker of renal function in diabetes mellitus. Ann Clin Biochem 1976; 24: 477-482.
17. Varghese SA, Powell TB, Budisavljevic MN, et al. Urine biomarkers predict the cause of glomerular disease. J Am Soc Nephrol 2007; 18: 913-922.
18. Berx G, Cleton-Jansen AM, Nollet F, et al. E-cadherin is a tumor/ invasion suppressor gene mutated in human lobular breast cancers. EMBO J 1995; 14: 6107-6115.
19. Shore EM, Nelson WJ. Biosynthesis of the cell adhesion molecule uvomorulin (E-cadherin) in Madin-Darby canine kidney epithelial cells. J Biol Chem 1991; 266: 19672-19680.
20. Gumbiner BM. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 1996; 84: 345-357.
21. Wijnhoven BP, Dinjens WN, Pignatelli M. E-cadherin-catenin cell-cell adhesion complex and human cancer. Br J Surg 2000; 87: 992-1005.
22. Hirohashi S, Kanai Y. Cell adhesion system and human cancer morphogenesis. Cancer Sci 2003; 94: 575-581.
23. Shariat SF, Matsumoto K, Casella R, Jian W, Lerner SP. Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder. Eur Urol 2005; 48: 69-76.
24. Protheroe AS, Banks RE, Mzimba M, et al. Urinary concentrations of the soluble adhesion molecule E-cadherin and total protein in patients with bladder cancer. Br J Cancer 1999; 80: 273-278.
25. Matsumoto K, Shariat SF, Casella R, Wheeler TM, Slawin KM, Lerner SP. Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. J Urol 2003; 170: 2248-2252.
26. Banks RE, Porter WH, Whelan P, Smith PH, Selby PJ. Soluble forms of the adhesion molecule E-cadherin in urine. J Clin Pathol 1995; 48: 179-180.
27. Piepenhagen PA, Nelson WJ. Biogenesis of polarized epithelial cells during kidney development in situ: roles of E-cadherin-mediated cell-cell adhesion and membrane cytoskeleton organization. Mol Biol Cell 1998; 9: 3161-3177.
28. Chen YT, Stewart DB, Nelson WJC. Coupling assembly of the E-cadherin/ beta-catenin complex to efficient endoplasmic reticulum exit and basal-lateral membrane targeting of E-cadherin in polarized MDCK cells. J Cell Biol 1999; 144: 687-699.
29. Lorz C, Benito-Martín A, Boucherot A, et al. The death ligand TRAIL in diabetic nephropathy. J Am Soc Nephrol 2008; 19: 904-914.
30. Melin J, Hellberg O, Akyürek LM, Källskog O, Larsson E, Fellström BC. Ischemia causes rapidly progressive nephropathy in the diabetic rat. Kidney Int 1997; 52: 985-991.
31. Bush KT, Tsukamoto T, Nigam SK. Selective degradation of E-cadherin and dissolution of E-cadherin-catenin complexes in epithelial ischemia. Am J Physiol Renal Physiol 2000; 278: F847-F852.
32. Steinhusen U, Weiske J, Badock V, Tauber R, Bommert K, Huber O. Cleavage and shedding of E-cadherin after induction of apoptosis. J Biol Chem 2001; 276: 4972-4980.
33. Burns WC, Twigg SM, Forbes JM, et al. Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol 2006; 17: 2484-2494.
34. Li JH, Wang W, Huang XR, et al. Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/ 2 MAP kinase signaling pathway. Am J Pathol 2004; 164: 1389-1397.